June 4, 2021

Humoral and Cellular Immune Response against SARS-CoV-2 Variants Following Heterologous and Homologous ChAdOx1 NCoV-19BNT162b2 Vaccination

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, vaccines

• [Pre-print, not peer-reviewed] A study of persons who received one dose of the AstraZeneca SARS-CoV-2 vaccine (N=129) found that a heterologous boost with the Pfizer-BioNTech vaccine induced significantly higher frequencies of spike-specific CD4 and CD8 T-cells and neutralizing antibodies compared to receipt of a second dose of AstraZeneca. These neutralizing antibodies were highly effective against B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) variants. The levels of antibodies produced by those receiving the Pfizer-BioNTech booster following AstraZeneca were similar to those among persons who received two doses of Pfizer-BioNTech. The authors recommend larger longitudinal studies to characterize the duration of immune responses and COVID-19-related clinical endpoints in persons receiving heterologous vaccinations. 

Barros-Martins et al. (June 3, 2021). Humoral and Cellular Immune Response against SARS-CoV-2 Variants Following Heterologous and Homologous ChAdOx1 NCoV-19BNT162b2 Vaccination. Pre-print downloaded Jun 4 from https://doi.org/10.1101/2021.06.01.21258172